Sinusoidal Obstruction Syndrome clinical trials

Explore recruiting sinusoidal obstruction syndrome clinical trials.

Recruiting sinusoidal obstruction syndrome studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Sinusoidal Obstruction Syndrome trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

AGORA-1 /ALFA 2100 study : A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD and/or FLT3-TKD relapse/refractory (R/R) AML

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia

Ireland, Belgium, Spain, Sweden, Finland, Netherlands +7 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Sinusoidal Obstruction Syndrome trials by city

Sinusoidal Obstruction Syndrome in Toronto Sinusoidal Obstruction Syndrome in Vancouver Sinusoidal Obstruction Syndrome in Montreal Sinusoidal Obstruction Syndrome in Calgary Sinusoidal Obstruction Syndrome in Edmonton Sinusoidal Obstruction Syndrome in Ottawa Sinusoidal Obstruction Syndrome in Winnipeg Sinusoidal Obstruction Syndrome in Quebec City Sinusoidal Obstruction Syndrome in Hamilton Sinusoidal Obstruction Syndrome in Kitchener Sinusoidal Obstruction Syndrome in London Sinusoidal Obstruction Syndrome in Halifax Sinusoidal Obstruction Syndrome in New York Sinusoidal Obstruction Syndrome in Los Angeles Sinusoidal Obstruction Syndrome in Chicago Sinusoidal Obstruction Syndrome in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease